←
Revolution Medicines46 posts
Revolution Medicines avatar✓

Revolution Medicines ✓

@RevMedicines

We aim to change the trajectory of disease for patients living with RAS-addicted cancers around the world. Community guidelines: bit.ly/4xUSQQs

◷ Joined August 2025▧ 41 Photos and videos
Revolution Medicines avatar
Revolution Medicines@RevMedicines·Nov 12

RAS mutations are linked to the development of many cancers, including pancreatic cancer and non-small cell lung cancer. Biomarker testing can identify specific RAS mutations, helping to inform treatment decisions. Learn more: expectras.com/

Post attachment
Revolution Medicines avatar
Revolution Medicines@RevMedicines·Nov 9

More than 60,000 people in the U.S. will be diagnosed with pancreatic cancer in 2026. This Pancreatic Cancer Awareness Month, we’re recognizing everyone affected by pancreatic cancer and the researchers working to better understand this complex disease.

Post attachmentPost attachmentPost attachmentPost attachment
Revolution Medicines avatar
Revolution Medicines@RevMedicines·Nov 5

Caregiving often happens quietly: coordinating appointments, managing everyday tasks and being there to listen. This National Family Caregivers Month, we recognize those supporting loved ones through pancreatic and lung cancer. Your well-being matters, too.

Post attachmentPost attachmentPost attachment
Revolution Medicines avatar
Revolution Medicines@RevMedicines·Nov 2

This November, we’re recognizing everyone affected by pancreatic and lung cancer. Together, we can spread awareness, show support, and make a difference.

Post attachment
Revolution Medicines avatar
Revolution Medicines@RevMedicines·Oct 22

We’re excited for ESMO2026, where we’ll share subgroup analyses from RASolute 302 and connect with colleagues across the oncology community. Swipe through to see where you can find Revolution Medicines throughout the congress. #ForMediaOnly

Post attachmentPost attachmentPost attachmentPost attachment
Revolution Medicines avatar
Revolution Medicines@RevMedicines·Oct 20

Patients have begun treatment in RASolve 308, a global Phase 3 trial evaluating our investigational RAS(ON) G12D-selective inhibitor plus pembrolizumab and platinum-based chemotherapy as first-line treatment for metastatic RAS G12D non-squamous NSCLC. revmed.com/media/news/13631/…

Post attachment
Revolution Medicines avatar
Revolution Medicines@RevMedicines·Oct 5

Congratulations to Jan Smith, PhD, Chief Scientific Officer, on this well-deserved recognition. Her leadership at RevMed brings together different perspectives and empowers teams to ask bold questions, follow the evidence, and advance science together.

Revolution Medicines avatar
Revolution Medicines@RevMedicines·Oct 5

Patient treatment is underway in RASolute 309, our global Phase 3 trial evaluating the combination of our RAS(ON) multi-selective inhibitor and investigational RAS(ON) G12D-selective inhibitor as first-line treatment for metastatic RAS G12D PDAC. More: revmed.com/media/news/13576/…

Post attachment
Revolution Medicines avatar
Revolution Medicines@RevMedicines·Sep 14

The U.S. FDA granted Breakthrough Therapy Designation to our RAS(ON) multi-selective inhibitor in combination with GnP for previously untreated metastatic pancreatic adenocarcinoma, an investigational treatment setting for this combination. Learn more: revmed.com/media/news/13431/…

Post attachment